Prime editing: A gene-editing technology based on the CRISPR/Cas system

• Use cultured mammalian cells compatible with transfection or electroporation, plasmid or mRNA/RNP delivery formats encoding a prime editor, pegRNA expression constructs or synthetic pegRNAs, optional nicking sgRNA expression constructs or synthetic sgRNAs for PE3/PE3b, genomic-DNA extraction reagents, PCR reagents for target-locus amplification, and sequencing-library reagents for edit quantification.

• For human pluripotent stem cells, published protocols used electroporation of prime-editing tools followed by MiSeq-based evaluation of the edited locus.

• Amplicon sequencing is the primary supported readout for quantifying precise edits, indels, and undesired products at the target locus, and Sanger sequencing can be used for lower-throughput locus verification when the expected edit is simple enough for chromatogram-based inspection.

• Fluorescent reporters or antibiotic selection should not be included as universal protocol requirements because their use is constructand study-specific rather than required for prime editing.

• Use standard mammalian cell-culture equipment, a transfection or electroporation system appropriate for the cell type, a thermocycler for target-locus PCR, gel or capillary electrophoresis equipment for PCR quality control, and a next-generation sequencing instrument such as MiSeq when quantitative edit, indel, and byproduct analysis is required.

• Computational guide-design tools such as PrimeDesign and pegFinder are literature-supported tools for generating candidate pegRNAs and nicking sgRNAs from reference and edited DNA sequences.

• Define the exact intended edit and retrieve the reference sequence around the target site, then design multiple candidate pegRNAs because editing efficiency depends strongly on target sequence, edit position, primer-binding-site sequence, reverse-transcription-template sequence, and cell context.

• Use PrimeDesign or pegFinder to nominate pegRNAs and optional nicking sgRNAs, and prioritize candidates that place the desired edit within the supported prime-editing design space while avoiding unsupported assumptions about a single universally optimal pegRNA.

• Prepare PE2, PE3, or PE3b according to the experimental goal: PE2 is the simplest condition for measuring pegRNA-driven editing, PE3 can increase editing by nicking the opposite strand, and PE3b can reduce premature second-strand nicking by using a nicking sgRNA that recognizes the edited sequence.

• Include a no-editor or no-guide negative control, a prime-editing-positive-control locus if available in the chosen cell type, and at least one non-targeting or edit-lacking control when the study design requires discrimination of true editing from sequencing or PCR background.

• Seed cells so they are healthy and compatible with the selected delivery method at the time of transfection or electroporation, then deliver the prime editor with the pegRNA and, for PE3 or PE3b, the nicking sgRNA.

• Because published studies use different cell types, delivery formats, and expression systems, use the cell-type-specific delivery conditions reported for the selected model rather than applying a universal voltage, reagent dose, or incubation condition.

• After delivery, culture cells for the post-editing interval used in the selected published protocol, then harvest cells for genomic DNA extraction and PCR amplification of the edited locus.

• Amplify a short genomic region spanning the edit site and sequence the amplicon to quantify the percentage of precise intended edits, wild-type alleles, indels, and unintended local byproducts.

• For higher efficiency, test several pegRNAs per edit and compare PE2, PE3, and PE3b when appropriate, because the founding and protocol literature show that prime-editing outcomes vary by target site, guide design, and second-strand nicking strategy.

• When conventional pegRNAs perform poorly, engineered pegRNAs with stabilizing 3' RNA motifs are literature-supported alternatives because 3' pegRNA degradation can reduce editing and epegRNAs improved editing in multiple mammalian cell types without increasing measured off-target editing in the reported study.

• Calculate precise editing as the fraction of sequencing reads containing the intended edit without undesired byproducts, calculate indels separately, and report undesired local products separately from precise edits.

• For PE3 experiments, interpret increased precise editing together with indel frequency because the second nick can increase desired editing but can also increase indels depending on locus and guide design.

• Report the exact prime editor version, delivery format, cell type, pegRNA spacer, PBS, RT template, nicking sgRNA sequence, time of harvest, sequencing method, and analysis criteria because prime-editing efficiency is context-dependent and not adequately described by the intended edit alone.

• Use biological replicates and present replicate-level editing values when comparing pegRNAs, PE systems, or optimization strategies.

Low or undetectable precise editing

• May be due to inefficient pegRNA design, as pegRNA activity varies with target sequence, edit position, PBS, and RT-template design.
• Solution:
Design and test multiple pegRNAs using PrimeDesign or pegFinder, compare PE2 and PE3/PE3b where appropriate, and quantify each candidate by targeted sequencing.

Low editing with otherwise valid pegRNA designs

• May result from degradation of the 3' pegRNA extension containing the PBS and RT template, reducing prime-editing activity.
• Solution:
Test engineered pegRNAs carrying stabilizing 3' structured RNA motifs, as epegRNAs improved editing efficiency in HeLa, U2OS, K562, and primary human fibroblasts in the reported study.

High indel fraction in PE3

• May arise from the additional nicking sgRNA increasing editing but also inducing indel formation at some loci.
• Solution:
Compare PE2, PE3, and PE3b, and prioritize conditions that maximize precise edit-to-indel ratio rather than precise edit percentage alone.

Variable performance across cell types or loci

• May be due to prime-editing outcomes depending on cellular and sequence determinants, including DNA repair context and pegRNA features.
• Solution:
Report locus-specific optimization data, test multiple guide designs, and avoid transferring exact performance expectations from one cell type or locus to another without empirical validation.